

2012

# Bone Health Management in Prostate Cancer Patients Receiving Androgen Deprivation Therapy

Vishnuprabha Dhanapal

David J. Reeves

*Butler University*, [dreeves@butler.edu](mailto:dreeves@butler.edu)

Follow this and additional works at: [http://digitalcommons.butler.edu/cophs\\_papers](http://digitalcommons.butler.edu/cophs_papers)

 Part of the [Oncology Commons](#), [Pharmaceutical Preparations Commons](#), and the [Pharmacy and Pharmaceutical Sciences Commons](#)

---

## Recommended Citation

Dhanapal, Vishnuprabha and Reeves, David J., "Bone Health Management in Prostate Cancer Patients Receiving Androgen Deprivation Therapy" (2012). *Scholarship and Professional Work – COPHS*. 210.  
[http://digitalcommons.butler.edu/cophs\\_papers/210](http://digitalcommons.butler.edu/cophs_papers/210)

This Article is brought to you for free and open access by the College of Pharmacy & Health Sciences at Digital Commons @ Butler University. It has been accepted for inclusion in Scholarship and Professional Work – COPHS by an authorized administrator of Digital Commons @ Butler University. For more information, please contact [omacisaa@butler.edu](mailto:omacisaa@butler.edu).

# Bone health management in prostate cancer patients receiving androgen deprivation therapy

**Vishnuprabha Dhanapal**

Henry Ford Hospital, Detroit, MI, USA

**David J Reeves**

St Vincent Indianapolis Hospital and Butler University, Indianapolis, IN, USA

## Abstract

**Purpose:** Patients receiving androgen deprivation therapy undergo a rapid decline in bone mineral density during the first 6 to 12 months of initiating therapy. The World Health Organization has developed and implemented the Fracture Risk Assessment Tool (FRAX) to predict the ten year risk of a major fracture & hip fracture. Additionally, the National Comprehensive Cancer Network and the National Osteoporosis Foundation have developed osteoporosis guidelines. This study aims to characterize the fracture risk (based on the FRAX tool) and the current management of bone health based on national guidelines compliance.

**Methods:** A retrospective chart review of patients receiving a LHRH agonist at our institution was conducted. Data collection commenced upon Institutional Review Board approval and included demographics, past medical history, medication regimen, history of androgen deprivation therapy, bone health and its management. The ten year fracture risk calculated with the collected information using the FRAX tool.

**Results:** A total of 174 subjects included with a mean age of 65.5 years, 71.8% had stage II prostate cancer, 97.7% received the LHRH agonist leuprolide for a mean of  $13.8 \pm 18.1$  months. In addition to ADT, 57% of patients had  $\geq 2$  risk factors for developing osteoporosis. The risk of sustaining a major fracture increased from 4% to 5.6% after the initiation of ADT ( $P = <0.001$ ). The risk for sustaining a hip fracture rose from 1.3% to 2.2% ( $P = <0.001$ ). National guideline compliance was found to be 9%, 5% and 3% respectively for obtaining Dual Energy X-ray Absorptiometry (DEXA) scans, calcium supplementation, and vitamin D supplementation.

**Conclusion:** In addition to predisposing risk factors for osteoporosis, ADT significantly increases the fracture risk in the prostate cancer population. There is room for improvement in the management of bone health as some intervention could have been made in over 90% of patients evaluated.

## Keywords

Androgen-deprivation therapy, osteoporosis, prostate cancer

## Background

Prostate cancer is the most common malignancy in males and the second leading cause of cancer-related mortality.<sup>1</sup> It is estimated that one in six men will develop prostate cancer in their lifetime.<sup>2</sup> However, the relative survival rates for prostate cancer are high: 100% at 5 years, 91% at 10 years, and 76% at 15 years.<sup>2</sup> Thus, minimizing the morbidity and mortality associated with the management of prostate cancer is at the forefront of caring for this population.

Management of prostate cancer is based on risk stratification and involves a variety of treatment strategies (Table 1). The proliferation of prostate cancer

cells is dependent on the binding of dihydrotestosterone, a derivative of testosterone with a higher binding affinity, to the androgen receptor. Androgen-deprivation therapy (ADT) (given as a depot luteinizing hormone-releasing agonist with or without an antiandrogen) is the recommended treatment for men with locally advanced prostate cancer, biochemical relapse after resection or radiation, and metastatic prostate cancer.<sup>3</sup> ADT can be achieved surgically *via* bilateral

---

### Corresponding author:

Vishnuprabha Dhanapal, Clinical Pharmacist Specialist – Hematology/Oncology, Henry Ford Hospital, Detroit, MI 48202, USA  
Email: Prabha400@gmail.com

**Table 1.** Prostate cancer risk stratification

| Risk         | Characteristics <sup>a</sup> | Treatment modalities            |
|--------------|------------------------------|---------------------------------|
| Low          | T1–T2a                       | Active surveillance             |
|              | Gleason $\leq$ 6             | Radical prostatectomy           |
|              | PSA $\leq$ 10 ng/mL          | External beam radiation         |
| Intermediate | T2b–T2c                      | ADT 4–6 months                  |
|              | Gleason 7                    |                                 |
| High         | PSA 10–20 ng/mL              |                                 |
|              | T3–T4                        | Radical prostatectomy           |
|              | Gleason 8 to 10              | External beam radiation         |
|              | PSA > 20 ng/mL               | ADT 2–3 years<br>Continuous ADT |

<sup>a</sup>Patient only needs to meet one of the criteria listed under 'Characteristics' to fall into risk category.

orchiectomy or pharmacologically (Table 2), most commonly utilizing luteinizing hormone-releasing hormone (LHRH) agonists. Adverse effects associated with ADT include: hot flashes, sexual dysfunction, hypogonadism, and osteoporosis.

Patients receiving ADT undergo a rapid decline in bone mineral density (BMD) during the first 6 to 12 months of initiating therapy. Osteoporosis is often under-diagnosed and under-prevented in men despite an estimated prevalence of 2 million and another 12 million men are at risk.<sup>4,5</sup> The major acquired causes of osteoporosis in men include: alcoholism, hypogonadism, and glucocorticoid therapy, of which the latter two are often found concomitantly in patients with prostate cancer. The use of ADT to manage prostate cancer indirectly and directly increases the fracture risk in this population. Indirectly, fracture risk is increased due to decreased muscle mass and increasing fall risk as a result of iatrogenic hypogonadism. The mechanism by which testosterone affects bone density is not completely understood. Androgens mediate osteoblast proliferation and differentiation, and increase bone matrix production and osteocalcin secretion presumably *via* the androgen receptor on osteoblasts.<sup>6</sup> Thus, ADT is believed to directly increase bone turnover and decrease BMD. Several prospective studies have established that BMD is significantly decreased in men receiving ADT in comparison to control groups. Interestingly, BMD loss in this population exceeded that seen in early menopause.<sup>7</sup> Fracture rates in men with prostate cancer who received ADT were described as a near-doubling of spinal fracture risk and a five-fold increase in hip fracture risk compared to matched controls.<sup>8,9</sup>

The World Health Organization (WHO) has developed and implemented the Fracture Risk Assessment Tool (FRAX) to predict the 10-year risk of a major fracture (defined as a fracture in the clinical spine,

**Table 2.** Pharmacologic agents utilized to achieve ADT

|                             |
|-----------------------------|
| Non-steroidal antiandrogens |
| Flutamide                   |
| Bicalutamide                |
| Nilutamide                  |
| Steroidal antiandrogens     |
| Megestrol                   |
| LHRH agonist                |
| Leuprolide                  |
| Goserelin                   |
| Triptorelin                 |
| LHRH antagonist             |
| Degarelix                   |
| Other                       |
| Ketoconazole                |

**Table 3.** National guideline recommendations<sup>a</sup>

|  |
|--|
| Patient counseling                                 |
| Smoking cessation                                  |
| Limiting alcohol consumption                       |
| Weight-bearing exercise                            |
| BMD testing  |
| Men 50 to 69 based on risk factors                 |
| All men $\geq$ 70 years old                        |
| Calcium and vitamin D supplementations             |
| Men $\geq$ 50 years calcium $\geq$ 1200 mg per day |
| Men $\geq$ 50 years vitamin D 800–1000 IU per day  |
| Bisphosphate therapy                               |
| FRAX risk $\geq$ 3% for hip fracture               |
| FRAX risk $\geq$ 20% for major fracture            |
| Osteopenia/osteoporosis on BMD                     |

<sup>a</sup>Based on guidelines created by the NOF and the NCCN.

shoulder, or forearm) and hip fracture.<sup>10</sup> The FRAX tool accounts for the patient's age, gender, body mass index (BMI), history of previous fracture in the patient or their parents, smoking status, alcohol consumption, and the presence of rheumatoid arthritis or other secondary risk for osteoporosis and BMD. Additionally, the WHO, National Osteoporosis Foundation (NOF), and the National Comprehensive Cancer Network (NCCN) created guidelines (Table 3) to prevent and manage osteoporosis.<sup>5,10,11</sup> This study aims to characterize the fracture risk (based on the FRAX tool) and the current management of bone health based on compliance to national osteoporosis guidelines.

## Methods

A retrospective chart review of patients receiving a LHRH agonist at our institution between 1 January 2007 and 1 January 2009 was identified *via* a pharmacy database. Patients were included if they were between 18 and 89 years, received at least one dose of a LHRH


**Table 4.** Demographics

|             |                     | Average $\pm$ SD | Range |
|-------------|---------------------|------------------|-------|
| Age (years) |                     | 65.5 $\pm$ 9.7   | 47–88 |
|             |                     | N                | %     |
| Race        | African American    | 105              | 60.3  |
|             | Caucasian           | 67               | 38.5  |
|             | Hispanic            | 2                | 1.1   |
| Smoking     | Current             | 39               | 22.4  |
|             | Former              | 50               | 28.7  |
| Alcohol     | $\geq 3$ drinks/day | 6                | 3.4   |
|             | $< 3$ drinks/day    | 168              | 96.6  |
| Stage       | Stage II            | 125              | 71.8  |
|             | Stage III           | 29               | 16.7  |
|             | Stage IV            | 20               | 11.5  |
| Agent       | Leuprolide          | 170              | 97.7  |
|             | Triptorelin         | 4                | 2.3   |

agonist between the above-mentioned dates, and had a diagnosis of prostate cancer. Patients with metastatic bone lesions or incomplete records were excluded. Electronic medical and paper records for these patients were reviewed retrospectively from the time care was initiated until either metastatic lesions were identified in the bones or 1 August 2009 (whichever occurred first). Data collection commenced upon Institutional Review Board approval and included demographics, past medical history, medication regimen, history of ADT, and bone health and its management. Collected information on bone health included: fracture history, BMD screening data, assessment of secondary risk factors for osteoporosis, and bone health management. The 10-year fracture risk was calculated with the collected information using the FRAX tool. Study endpoints included characterizing the fracture risk in the prostate cancer population receiving ADT utilizing the FRAX tool and characterizing the current management of bone health based on osteoporosis guideline compliance. Duration of ADT was calculated based on the total exposure for patients receiving continuous hormone therapy and duration of the most recent cycle of ADT in patients being treated intermittently. Descriptive statistics were used for demographic data analysis and to characterize the current management of bone health. Paired *t*-test was used to compare 10-year fracture pre- and post-ADT (where  $p < 0.05$  identifies a significant value).

## Results


A total of 462 charts were reviewed, of which 174 subjects were included in the study with a mean age of 65.5

**Figure 1.** Risk factors for osteoporosis.

years. The remaining patients were excluded for the following reasons: presence of bone metastasis ( $n = 213$ ), age  $> 89$  ( $n = 43$ ), and incomplete records ( $n = 32$ ). The majority (71.8%) of patients had stage II prostate cancer at the time of initial diagnosis and received a LHRH agonist for a mean of  $13.8 \pm 18.1$  months. The group with stage II disease at diagnosis comprised patients receiving ADT intermittently for biochemical relapse (57.9%), neoadjuvantly to radiation or surgery (33.4%), and continuously for cancer progression (8.7%). Demographic data are summarized in Table 4. Fifty-four percent of patients received ADT for less than 6 months, while 20% and 26% of the patients received 7 to 12 months and  $> 12$  months of ADT, respectively.

In addition to ADT, 57% of the patients had  $\geq 2$  additional risk factors for developing osteoporosis (Figure 1). The risks factors assessed were age over 70, Caucasian ancestry, BMI  $< 25$ , smoking/alcohol intake, steroid exposure, and secondary risk factors for osteoporosis development (excluding ADT). Utilizing the FRAX tool, the 10-year estimated fracture risk was calculated. The risk for developing a major fracture, defined as fracture of the clinical spine, shoulder, or forearm, increased from 4% prior to ADT to 5.6% after the initiation of ADT ( $p \leq 0.001$ ). Similarly, the risk for sustaining a hip fracture rose from 1.3% to 2.2% ( $p \leq 0.001$ ).

General counseling regarding adverse effects associated with ADT was documented in 15% and another 16% received specific counseling regarding the effects of ADT on bones. Bone health assessment was not documented in 69% of patients. Compliance to national osteoporosis guideline recommendations was found to be 9%, 5%, and 3% for obtaining dual energy X-ray absorptiometry (DEXA) scans, calcium supplementation, and vitamin D supplementation (Figure 2). Bisphosphonate therapy was indicated in 10% of the patients, of which 40% received one. Overall compliance (defined as obtaining a DEXA scan,



**Figure 2.** Compliance to national guideline measures.

supplementing calcium, vitamin D, and administration of a bisphosphonate if indicated) was 3.9%.


Nine percent of patients ( $n=15$ ) were documented to have undergone a DEXA scan and results were available for nine patients. The average age of patients was  $77.2 \pm 4.6$  years, 50% were Caucasian, and the average BMI was 27.2. Patients receiving a DEXA scan were on ADT for an average of 31.5 months. The FRAX score in this population accounting for ADT for sustaining a major fracture was 6.1% and 2.7% for hip fracture (Figure 3). Sixty-six percent of patients had a BMD in the osteopenic or osteoporotic range. Calcium and vitamin D supplementations were indicated in all these patients and supplemented in 22% of them. Bisphosphonate therapy was indicated in six patients and initiated in 3.

## Discussion

Fractures lead to back pain, decreased functional capacity, increased risk of future fractures, higher health care costs, and increased incidence of institutionalization and hospitalizations.<sup>12,13</sup> Additionally, fractures in men are associated with a decreased quality of life and increased mortality.<sup>14</sup> The overall healthcare costs associated with osteoporosis has been estimated to approach \$17 billion annually.<sup>13</sup>

Metastatic prostate cancer bone lesions lead to bone disruption and pathological fractures, which are an important cause of morbidity. Initiation of adjunctive bisphosphonate in this subpopulation is a standard of care to prevent skeletal-related events.<sup>15</sup> Our study focused on osteoporotic risk rather than on pathological fractures as a consequence of the treatment of prostate cancer. In an effort to decrease confounders, patients with metastatic bone lesions were excluded. The demographics of the population evaluated in this study is similar to those of other studies evaluating osteoporosis in men receiving ADT.<sup>16–19</sup>

Many patients presenting with prostate cancer have pre-existing risk factors for sustaining a fracture prior



**Figure 3.** FRAX 10-year estimated fracture risk.

to the initiation of ADT. In fact, over 70% of all prostate cancer cases occur in men >65 years of age with a median age of 68 years.<sup>20</sup> Pre-existing osteopenia/osteoporosis, subclinical vitamin D deficiency, and a plethora of comorbidities are also found in this population.<sup>21</sup> Unmodifiable risk factors identified in this study population included median age and Caucasian ancestry. Other identified risk factors include previous or current smoking status, BMI < 25 kg/m<sup>2</sup>, and secondary risk factors (i.e., osteogenesis imperfecta, diabetes mellitus type 1, drugs (excluding ADT)). Fifty-seven percent of patients had  $\geq 2$  assessable risk factors. However, the true number of risk factors is most likely higher, given the retrospective nature of this study and the lack of documentation regarding secondary risk factors.

BMD is considered the gold standard for diagnosing and assessing management of osteoporosis.<sup>22</sup> The duration of ADT directly correlates to the magnitude of decrease in BMD and subsequently to increased fracture risk. An analysis of over 50,000 men from the Surveillance, Epidemiology and End Results (SEER) program and Medicare databases compared the risk of fracture in men with a diagnosis of prostate cancer who were treated with ADT versus those not receiving ADT.<sup>23</sup> No differences between study arms were detected in the year prior to ADT initiation. However, the proportion of patients with osteoporosis (6.92% vs. 3.69%,  $p < 0.001$ ), fracture (19.37 vs. 12.63,  $p < 0.001$ ), and fracture resulting in hospitalization (5.19% vs. 2.37%,  $p < 0.001$ ) was higher in the ADT arm 1–5 years after treatment compared to patients who did not receive ADT. The risk of fracture was also found to directly correlate with the number of doses of LHRH agonist received. Due to the retrospective nature of our study, only a snapshot of androgen exposure was assessed. At first glance, over half the patients received ADT for  $\leq 6$  months. However, over 50% of the population was receiving intermittent hormone therapy (IHT) and only the last cycle (defined as therapy resuming after a break of greater 3 months)

was used to calculate duration. Therefore, the total exposure to ADT is likely to be greater than the calculated value. This method of calculating duration was selected as many patients were on IHT for numerous years and previously managed at other facilities; hence records were not available. Although increased duration of ADT directly correlates to increasing risk, studies also indicate that the greatest rate in decline in BMD is actually within the first 6–12 months of ADT.<sup>24</sup> Additionally, recent studies support extended duration of ADT and the direct correlation between duration and significance of adverse effects is well documented.<sup>25–27</sup> Thus, the overwhelming majority of patients with prostate cancer are at risk for bone-related complications upon the initiation of ADT.

Calcium and vitamin D supplementations are known to improve BMD and ultimately decrease fracture incidence.<sup>28,29</sup> Supplementations of both calcium and vitamin D are recommended for the majority of patients receiving ADT. Caution is needed when supplementing calcium in patients with metastatic bone lesions, as these patients are at risk for developing hypercalcemia. Bisphosphonate therapy is recommended in prostate cancer patients receiving ADT with a  $\geq 20\%$  risk of a major fracture or  $\geq 3\%$  risk of hip fracture based on FRAX score.<sup>5,10,11</sup> Although long-term data on the incidence of fracture in men with prostate cancer treated with bisphosphonate therapy are unavailable, short-term results support its use.<sup>30</sup> Our study indicates that calcium and vitamin D supplementations were indicated in the overwhelming majority of patients; however, they were rarely provided. Similarly, our study shows that there is room for improvement in bisphosphonate supplementation.

A retrospective study conducted by Tanvetyanon evaluated 184 patients receiving ADT for  $\geq 1$  year to identify independent predictors of receiving at least one physician initiated intervention to prevent or treat osteoporosis.<sup>21</sup> Interventions evaluated included: BMD evaluation *via* DEXA scan, initiation of bisphosphonates, calcium, vitamin D, calcitonin, or estrogen. Similar to the results of our study, most patients had multiple risk factors for osteoporosis and the majority of patients did not receive any intervention. Thirty-three physicians made 58 interventions in 27 patients. Overall, 14.7% of patients (95% CI, 9.5 –20.0%) received at least one intervention. In our study, 12.6% of the patients received at least one intervention. Of the six patients that received a DEXA scan in the above study, five had osteoporosis and one had osteopenia. The only predictor of receiving an intervention was the presence of bone metastasis. Fifty-one percent of interventions were made by primary care physicians, 27.3% by non-oncology related specialists, and 21.2% by oncologists. Inability to assess primary care

interventions is a limitation to our study as it was conducted at an independent cancer center without complete access to records of non-oncology related physicians. Thus, interventions made outside our institution may not have been documented.

The FRAX tool, validated assessment software created by the WHO, predicts the 10-year estimated fracture risk based on known clinical risk factors with or without BMD test results.<sup>31</sup> To the investigators' knowledge, our study is the first study characterizing the fracture risk in the prostate cancer population utilizing the FRAX tool. As hypothesized, including ADT as a secondary risk factor significantly increased the 10-year risk of both a major fracture and a hip fracture. Even with the addition of ADT to the risk calculation, the average 10-year risk of sustaining a major fracture was well below the 20% threshold necessitating bisphosphonate supplementation per guidelines. However, the median 10-year risk for sustaining a hip fracture with the addition of ADT was 2.7%, trending toward the 3% risk necessitating bisphosphonate therapy. One of the major limitations of the FRAX tool is the need to primarily input dichotomous data. The tool is unable to account for extent of exposure to glucocorticoid, alcohol, smoking, or ADT. Additionally, minimal information regarding family history of fractures was identified in the medical records; thus, the tool assumed that this risk was not present. Therefore, the estimated 10-year fracture risk maybe underestimated in our population.

Compliance to national guidelines was assessed in five areas: obtaining a DEXA scan, supplementation of calcium, supplementation of vitamin D, bisphosphonate therapy, and overall compliance (defined as meeting all four previously mentioned interventions in indicated patients). Baseline assessment by clinicians was identified as either general (mention of discussion of adverse effects (ADRs) associated with ADT) or specific (documentation of discussion of specifically bone-related risks, documentation of calcium/vitamin D addition, bisphosphonate therapy, or obtaining DEXA scan). Low compliance to guideline measures may be subsequent to the lack of risk perception. Osteoporosis is frequently considered a disease of small-framed Caucasian or Asian elderly women. Sixty-nine percent of patients had no documentation of discussion of adverse effects associated with ADT. Additionally, due to the primary concern of preventing further spread of malignancy, the management of ADRs, specifically bone-health complications which remain silent until fracture incidence, may not be at the forefront of priorities. The management of prostate cancer is truly multidisciplinary as patients are seen by one of or a combination of medical oncology, radiation oncology, and surgical oncology services, increasing the difficulty of managing complications. Due to the

retrospective nature of this study, the low compliance rates may also be due to a lack of documentation. One method to improve compliance is educating the clinicians about the fracture risk in this population and available preventative measures.

Similar to our study, Wilcox et al.<sup>32</sup> conducted a retrospective analysis of veterans with prostate cancer receiving ADT to characterize risk factors and management of bone health in this population. A total of 174 patients were included with a mean age of 76, and the mean duration of ADT was 21 months. Thirteen percent of men underwent a DEXA scan, 19% received calcium and vitamin D supplementations, and 11% of the patients received bisphosphonate therapy. Investigators concluded this population has pre-existing risk factors for osteoporosis and received inadequate evaluation and treatment for osteoporosis.

Of the patients receiving a DEXA scan within our institution, 2/3 had osteopenia or osteoporosis. When reviewing the characteristics of these patients, it was easily noted these patients were at high risk based on age and BMI alone. However, DEXA scans were not ordered at baseline but, rather, only after patients received ADT for a prolonged period of time. DEXA scans were ordered for confirmation of clinical assessment rather than for prevention or treatment. No subsequent follow-up scans were conducted to evaluate management strategies.

## Conclusion

Traditionally considered a comorbidity in the elderly female population, this study has characterized the substantial bone-health related complications in the prostate cancer population receiving ADT. However, the true risk is likely much greater as discussed above. There is great room for improvement in compliance to national guidelines as some intervention could have been made in over 90% of patients evaluated. Educating the multidisciplinary teams caring for prostate cancer patients regarding the risk of bone-related complications is one modality of optimizing care. As pharmacist-driven initiatives, collaborative practice agreement, and medication therapy management become routine responsibilities of the profession, optimization of the prevention and management of osteoporosis in prostate cancer patients receiving ADT can and should be actively incorporated in to daily practice.

## References

1. Jemal A, Siegel R, Ward E, et al. Cancer Statistics. *Ca Cancer J Clin* 2009; 59: 225–249.
2. American Cancer Society. What are the key statistics about prostate cancer? 2010, [http://www.cancer.org/docroot/cric/content/cric\\_2\\_4\\_1x\\_what\\_are\\_the\\_key\\_statistics\\_for\\_prostate\\_cancer\\_36.asp](http://www.cancer.org/docroot/cric/content/cric_2_4_1x_what_are_the_key_statistics_for_prostate_cancer_36.asp) (accessed 15 January 2011).

3. Fowler Jr. JE, Bigler SA, White PC, et al. Hormone therapy for locally advanced prostate cancer. *J Urol* 2002; 168: 546–549.
4. Ebeling PR. Clinical practice. Osteoporosis in men. *N Engl J Med* 2008; 358: 1474–1482.
5. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Prostate Cancer. V.1.2010. Fort Washington, PA: National Comprehensive Cancer Network; 2010. [http://www.nccn.org/professionals/physician\\_gls/PDF/prostate.pdf](http://www.nccn.org/professionals/physician_gls/PDF/prostate.pdf) (accessed 15 February 2010).
6. Wiro K and Orwoll E. Androgens and bone: basic aspects. In: Orwoll E (ed.) *Osteoporosis in Men*. San Diego: Academic Press, 1999, pp. 211–274.
7. Higano CS. Bone loss and the evolving role of bisphosphonate therapy in prostate cancer. *Urol Oncol* 2003; 21: 392–398.
8. Baillie SP, Davison CE, Johnson FJ, et al. Pathogenesis of vertebral crush fractures in men. *Age Ageing* 1992; 21: 139–141.
9. Jackson JA and Spiekerman AM. Testosterone deficiency is common in men with hip fracture after simple falls. *Clin Res* 1989; 37: 131–136.
10. World Health Organization. Fracture Risk Assessment Tool. <http://www.sheffield.ac.uk/FRAX/> (accessed January 2010)
11. National osteoporosis foundation. The clinician's guide to prevention and treatment of osteoporosis. [http://www.nof.org/professionals/pdfs/NOF\\_ClinicianGuide2009\\_v7.pdf](http://www.nof.org/professionals/pdfs/NOF_ClinicianGuide2009_v7.pdf) (accessed January 2010).
12. Higano CS. Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really now? *Nat Clin Pract Urol* 2008; 5(1): 24–34.
13. Orsini LS, Rousculp MD, Long SR, et al. Health care utilization and expenditures in the United States: a study of osteoporosis-related fractures. *Osteoporos Int* 2005; 16(4): 359–371.
14. Center JR, Nguyen TV, Schneider D, et al. Mortality after all major types of osteoporotic fracture in men and women: an observational study. *Lancet* 1999; 353(9156): 878–882.
15. Saad F, Gleason DM, Murray R, et al. Zoledronic acid prostate cancer study group: a randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. *J Natl Cancer Inst* 2002; 94: 1458–1468.
16. Ryan CW, Huo D, Stallings JW, et al. Lifestyle factors and duration of androgen deprivation affect bone mineral density of patients with prostate cancer during first year of therapy. *Urology* 2007; 70(1): 122–126.
17. Smith MR, McGovern FJ, Zietman AL, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. *N Engl J Med* 2001; 345(13): 948–955.
18. Smith MR, Eastham J, Gleason DM, et al. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. *J Urol* 2003; 169(6): 2008–2012.

19. Michaelson MD, Kaufman DS, Lee H, et al. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. *J Clin Oncol* 2007; 25(9): 1038–1042.
20. American Cancer Society. Cancer Facts and Figures 2010 [www.cancer.org/downloads/STT/Cancer\\_Facts\\_and\\_Figures\\_2010.pdf](http://www.cancer.org/downloads/STT/Cancer_Facts_and_Figures_2010.pdf) (accessed March 2010).
21. Tanvetyanon T. Physician practices of bone density testing and drugprescribing to prevent or treat osteoporosis during androgen deprivation therapy. *Cancer* 2005; 103: 237–241.
22. Diamond TH, Higano CS, Smith MR, et al. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. *Cancer* 2004; 100: 892–899.
23. Shahinian VB, Kuo Y-F, Freeman JL, et al. Risk of fracture after androgen deprivation for prostate cancer. *N Engl J Med* 2005; 352: 154–164.
24. Greenspan SL, Coates P, Sereika SM, Nelson JB, Trump DL and Resnick NM. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. *J Clin Endocrinol Metab* 2005; 90: 6410–6417.
25. Bolla M, Theodorides M, de Reijke, et al. Duration of androgen suppression in the treatment of prostate cancer. *N Engl J Med* 2009; 360: 2516–2527.
26. Horwitz EM, Bae KY, Hanks GE, et al. Ten-year follow-up of RTOG 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. *J Clin Oncol* 2008; 26(15): 2497–2504.
27. Souhami L, Bae K, Pilepich M, et al. Impact of the duration of adjuvant hormonal therapy in patients with locally advanced prostate cancer treated with radiotherapy: a secondary analysis of RTOG 85–31. *J Clin Oncol* 2009; 27: 2137–2143.
28. Dawson-Hughes B, Harris SS, Krall EA, et al. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age and older. *N Engl J Med* 1997; 337: 670–676.
29. Trivedi DP, Doll R and Tee Khaw K. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomized double blind controlled trial. *BMJ* 2002; 326: 469.
30. Smith MR, Eastham J, Gleason DM, et al. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. *J Urol* 2003; 169: 2008–2012.
31. Kanis JA, Borgstrom F, De Laet C, et al. Assessment of fracture risk. *Osteoporos Int* 2005; 16: 581–589.
32. Wilcox A, Carnes ML, Moon TD, et al. Androgen deprivation in veterans with prostate cancer: implications for skeletal health. *Ann Pharmacother* 2006; 40: 2107–2114.